Results 71 to 80 of about 101,444 (326)
Abstract Background and Aims Peroxisome proliferator‐activated receptor α (PPARα) regulates fatty acid transport and catabolism in liver. However, the role of intestinal PPARα in lipid homeostasis is largely unknown. Here, intestinal PPARα was examined for its modulation of obesity and NASH. Approach and Results Intestinal PPARα was activated and fatty
Tingting Yan +22 more
wiley +1 more source
Mixed dyslipidemias in primary care patients in France
Laurent Laforest1, Baishali M Ambegaonkar2, Thierry Souchet3, Vasilisa Sazonov2, Eric Van Ganse11Lyon University, Lyon, France; 2Merck and Co Inc, Whitehouse Station, NJ, USA; 3Merck, Sharp & Dohme, Paris, FranceObjective: To determine the ...
Laforest L +4 more
doaj
In Situ Lipoprotein‐seeking Dye for in Vivo Real‐Time Imaging of Lipid Dysregulation Diseases
This study develops lipoprotein‐seeking NIR‐II dyes that specifically bind circulating lipoproteins. These dyes form ultra‐stable complexes with endogenous lipoprotein, enabling real‐time, high‐contrast imaging of fatty liver and atherosclerotic plaques. Tunable binding kinetics allow customized imaging windows.
Yijing Du +6 more
wiley +1 more source
NAFLD‐related hepatocellular carcinoma: The growing challenge
Risk and protective factors for NAFLD‐related hepatocellular carcinoma Abstract Hepatocellular carcinoma (HCC) is a common cause of cancer‐related mortality and morbidity worldwide. With the obesity pandemic, NAFLD‐related HCC is contributing to the burden of disease exponentially.
Pir Ahmad Shah +2 more
wiley +1 more source
Differential lipid metabolism in monocytes and macrophages: influence of cholesterol loading[S]
The influence of the hypercholesterolemia associated with atherosclerosis on monocytes is poorly understood. Monocytes are exposed to high concentrations of lipids, particularly cholesterol and lysophosphatidylcholine (lyso-PC).
Irene Fernandez-Ruiz +4 more
doaj +1 more source
Impact of nutrients and food components on dyslipidemias: what is the evidence?
Dyslipidemias have been shown to bear a close association with an increased risk of cardiovascular diseases, atherosclerosis in particular. As efforts are being made to find alternative therapies and ways to prevent disease, there is a corresponding rise
C. Rosa +4 more
semanticscholar +1 more source
Integrin β3 Orchestrates Hepatic Steatosis via a Novel CD36‐Dependent Lipid Uptake Complex
In MASH, ITGB3 recruits LYN and drives its ubiquitin‐proteasomal degradation via phosphorylation. This relieves DHHC5 inhibition, enabling ITGB3/DHHC5/CD36 complex assembly to enhance CD36 palmitoylation and fatty acid uptake, thereby exacerbating disease. Targeting ITGB3 blocks this pathogenic axis and ameliorates MASH.
Ying Zhang +13 more
wiley +1 more source
Steatotic HCC can be diagnosed by MRI and forms a pro‐tumor immune microenvironment with high expression of PD‐L1, M2 polarization of macrophages and activation of CAFs, which may be a good target for combined immunotherapy. Abstract Background and Aims Immunotherapy has become the standard‐of‐care treatment for hepatocellular carcinoma (HCC), but its ...
Hiroki Murai +29 more
wiley +1 more source
Therapeutic Gene Editing in Dyslipidemias
Dyslipidemia, characterized by abnormal lipid levels in the blood, significantly escalates the risk of atherosclerotic cardiovascular disease and requires effective treatment strategies.
Seyed Saeed Tamehri Zadeh +1 more
doaj +1 more source
This study develops an mRNA therapy encoding a long‐acting GLP‐1/FGF21 fusion protein. A three‐tailed ionizable lipid engineered three‐component lipid nanoparticle delivers the mRNA to inguinal adipose tissue. In obese mice, this targeted, dual‐hormone treatment potently reduces body weight, fat mass, presenting a localized strategy for metabolic ...
Bin Ma +10 more
wiley +1 more source

